Neal Shore
Articles
-
2 months ago |
urotoday.com | Neal Shore
Read the Full Video TranscriptZach Klaassen: Hi, my name is Zach Klaassen. I'm a urologic oncologist at the Georgia Cancer Center in Augusta, Georgia.
-
Nov 8, 2024 |
onclive.com | Neal Shore
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Atlantic Urology Clinics, discusses early data from the phase 1/2 Duravelo-1 trial (NCT04561362) investigating zelenectide pevedotin (formerly BT8009) in patients with metastatic urothelial carcinoma. He also highlights the rationale for the ongoing phase 2/3 Duravelo-2 trial (NCT06225596).
-
Oct 28, 2024 |
urologytimes.com | Neal Shore
OpinionVideoOctober 28, 2024Treatment Considerations for PSMA-Positive mCRPC PatientsNeal Shore, MD, FACS, highlights the exciting advancements in radioligand therapy for prostate cancer, noting that ongoing trials are exploring its use in various disease stages and settings, and emphasizes the importance of reviewing the VISION and FORE trial publications for further insights.
-
Oct 22, 2024 |
urologytimes.com | Neal Shore
OpinionVideoOctober 21, 2024Advancing Prostate Cancer Treatment With Lutetium 617 and PSMA PET ImagingNeal Shore, MD, FACS, discusses the evolving use of follow-up PSMA PET scans and the recent FORE trial, which showed that Lutetium-177 improves radiographic progression-free survival and PSA levels in prechemotherapy patients with mCRPC, with more data on overall survival and quality of life expected.
-
Oct 14, 2024 |
urologytimes.com | Neal Shore
OpinionVideoOctober 14, 2024Sequencing Treatment and Optimizing Care in mCRPC: Insights From VISION and TheraP TrialsNeal Shore, MD, FACS, emphasizes the significance of the VISION and TheraP trials in supporting the FDA approval of Lutetium-177 for patients with mCRPC who have undergone androgen receptor inhibitor and taxane treatments, highlighting the role of PSMA PET imaging in treatment sequencing and patient selection.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →